EU calls for tougher warnings on antidepressants for kids

A committee of experts in Europe are calling for strong warnings to be placed on two classes of antidepressants, informing doctors and parents of the risk they could pose to children and adolescents.

A European Medicines Agency expert committee concluded that Prozac-type serotonin-selective reuptake inhibitors (SSRI) and serotonin-norepinephrine reuptake inhibitors (SNRI) were associated with increased suicide-related behaviour and hostility in young people.

The London-based watchdog says they are recommending the inclusion of strong warnings across the whole of the European Union to doctors and parents about these risks and will advise doctors and parents that these products should not be used in children and adolescents except in their approved indications.

This action is the latest indication of a worldwide clampdown on the use of Prozac-type pills in teenagers after research has produced evidence that the drugs can lead to an increased incidence of suicide attempts, suicidal thoughts and anger.

For the most part the drugs were initially approved for only treating adults in the European Union, but doctors have sometimes used them "off-label" in children. A few of the products are licensed for paediatric use in treating obsessive-compulsive disorder and one of them, Eli Lilly and Co's Strattera, is approved for the treatment of attention deficit hyperactivity disorder.

Martin Harvey, an agency spokesman says the new warnings would not prevent the use of these medicines in such approved settings.

No sign of a link to suicide-related behaviour and the use of Strattera, has been established says the agency but experts concluded the drug should carry a warning reflecting an increased risk of side-effects such as hostility.

Other medicines covered by the European review included GlaxoSmithKline Plc's Paxil, or Seroxat; Lundbeck's two drugs Celexa and Lexapro; Pfizer Inc's Zoloft; Wyeth's Effexor; Akzo Nobel's Remeron; and two other medicines from Lilly, Cymbalta and Prozac.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
How bedtime screen use affects sleep in early adolescents